Patients with cardiac diseases ongoing or in the past  months (e.g. congestive heart failure, acute myocardial infarction, significant uncontrolled arrhythmias) are not eligible for this trial
Has a medical history of myocardial infarction within  months, symptomatic congestive heart failure
Evidence or history of significant cardiac disease (such as, but not limited to, unstable angina pectoris, myocardial infarction within the prior  months, heart failure within  months, symptomatic congestive heart failure, symptomatic or uncontrolled arrhythmias, severe aortic stenosis, symptomatic mitral stenosis).
Patients with cardiac diseases ongoing or in the past  months (e.g. congestive heart failure, acute myocardial infarction, significant uncontrolled arrhythmias) are not eligible for this trial
Patient has significant abnormalities on screening electrocardiogram (EKG) and active and significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, hypertension, valvular disease, pericarditis, or myocardial infarction within  months of screening
Have serious medical illnesses including, but not limited to, congestive heart failure, myocardial infarction or cerebral vascular accident within the last six months, or life threatening cardiac arrhythmias.
Cardiac disease ongoing or in the past  months (e.g. congestive heart failure, acute myocardial infarction, significant uncontrolled arrhythmias)
uncontrolled or severe cardiovascular disease, including recent (< months) myocardial infarction or congestive heart failure,
Patients with a history of cardiac disease including: () uncontrolled angina, congestive heart failure, or myocardial infarction within six months prior to study entry, () congenital long QT syndrome, () clinical significant ventricular arrhythmias
Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening.
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening
Known congestive heart failure, significant ventricular arrhythmias, cirrhosis, grade / chronic kidney disease, uncontrolled diabetes
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of starting study drug
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening
History of congestive heart failure or myocardial infarction within the previous six months
Significant or uncontrolled congestive heart failure (CHF), myocardial infarction or significant ventricular arrhythmias within the last six months.
Significant or uncontrolled congestive heart failure (CHF), myocardial infarction, significant ventricular arrhythmias within the last six months or significant pulmonary dysfunction.
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening
Significant or uncontrolled congestive heart failure (CHF), myocardial infarction or significant ventricular arrhythmias within the last six months.
Heart failure or significant heart disease including significant arrhythmias, myocardial infarction within the last  months, unstable angina, documented ejection fraction < %, or current digoxin therapy
Cardiovascular Acute myocardial infarction Congestive heart failure - (NYHA criteria for uncontrolled) Clinically significant cardiac arrhythmias - uncontrolled
Patients who have had myocardial infarction, severe congestive heart failure, or significant arrhythmia within the past  months.
Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within  months of screening
Patient has significant abnormalities on screening electrocardiogram (EKG) and active and significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, hypertension, valvular disease, pericarditis, or myocardial infarction within  months of screening
